Neoadjuvant therapy

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et Read More

2025-12-16T10:39:58-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et Read More

2025-12-15T13:52:56-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|
Go to Top